1. Home
  2. DRVN vs MESO Comparison

DRVN vs MESO Comparison

Compare DRVN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Driven Brands Holdings Inc.

DRVN

Driven Brands Holdings Inc.

HOLD

Current Price

$13.20

Market Cap

2.0B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$13.76

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRVN
MESO
Founded
1972
2004
Country
United States
Australia
Employees
N/A
81
Industry
Automotive Aftermarket
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
DRVN
MESO
Price
$13.20
$13.76
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$18.33
N/A
AVG Volume (30 Days)
1.5M
127.7K
Earning Date
05-12-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
146.70
N/A
EPS
0.33
N/A
Revenue
$1,862,438,000.00
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
$1.53
$30.65
P/E Ratio
$40.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.80
$9.88
52 Week High
$19.74
$21.50

Technical Indicators

Market Signals
Indicator
DRVN
MESO
Relative Strength Index (RSI) 48.49 40.57
Support Level $12.57 $13.48
Resistance Level $13.54 $16.59
Average True Range (ATR) 0.62 0.46
MACD -0.03 -0.07
Stochastic Oscillator 29.40 4.00

Price Performance

Historical Comparison
DRVN
MESO

About DRVN Driven Brands Holdings Inc.

Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: